<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">bjcvs</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27074268</article-id><article-id pub-id-type="pmc">5062689</article-id><article-id pub-id-type="doi">10.5935/1678-9741.20150092</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Comparison of Transcatheter Aortic Valve Implantation
<italic>versus</italic> Surgical Aortic Valve Replacement to Improve Quality
of Life in Patients &#x0003e;70 Years of Age with Severe Aortic
Stenosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kocaaslan</surname><given-names>Cemal</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ketenci</surname><given-names>B&#x000fc;lend</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Y&#x00131;lmaz</surname><given-names>Mehmet</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kehlibar</surname><given-names>Tamer</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Memeto&#x0011f;lu</surname><given-names>Mehmet Erdem</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/></contrib><contrib contrib-type="author"><name><surname>Erta&#x0015f;</surname><given-names>G&#x000f6;khan</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Eren</surname><given-names>Mehmet</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Demirta&#x0015f;</surname><given-names>Mahmut Murat</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label>Dr.Siyami Ersek Cardiovascular and Thoracic Surgery
Hospital, &#x00130;stanbul, Turkey.</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Mehmet Erdem Memeto&#x0011f;lu, Akdeniz
University School of Medicine/Department of Cardiovascular Surgery,
Dumlup&#x000c4;nar Boulevard, 07058 - Antalya Campus - Antalya, Turkey. E-mail:
<email>dr.m.erdem07@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2016</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2016</year></pub-date><volume>31</volume><issue>1</issue><fpage>1</fpage><lpage>6</lpage><history><date date-type="received"><day>10</day><month>7</month><year>2015</year></date><date date-type="accepted"><day>15</day><month>12</month><year>2015</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective:</title><p>Transcatheter aortic valve implantation has recently been used in the
treatment of severe aortic valve stenosis, particularly in patients with
high mortality and morbidity rates for open surgery. The purpose of this
study was to compare quality of life in patients over 70 years of age
undergoing surgical or transcatheter aortic valve implantation, before the
procedure and in the early post-procedural period.</p></sec><sec><title>Methods:</title><p>Seventy-nine patients were included in the study, 38 (48.1%) male and 41
(51.9%) female. Mean age of patients was 74.3&#x000b1;5.2 (70-91) years. The
surgical aortic valve replacement group consisted of 51 (64.6%) patients and
the transcatheter aortic valve replacement group of 28 (35.4%). Quality of
life data before the procedure and at the 3<sup>rd</sup> month
postoperatively in patients aged 70 years and older undergoing surgical or
transcatheter aortic valve implantation were assessed using the 36-item
Short Form Health Survey form.</p></sec><sec><title>Results:</title><p>Positive increases in physical task difficulty (13.2&#x000b1;9.8
<italic>vs.</italic> 5.1&#x000b1;7.3) (<italic>P</italic>=0.001),
emotional task difficulty (14.4&#x000b1;11.9 <italic>vs.</italic>
8.5&#x000b1;6.4) (<italic>P</italic>=0.035), and mental health
(0.4&#x000b1;10.4 <italic>vs.</italic> 9.6&#x000b1;15.1)
(<italic>P</italic>=0.001; <italic>P</italic>&#x0003c;0.01) scores in patients
undergoing transcatheter aortic valve replacement were significantly higher
compared to the surgical aortic valve replacement group. No statistically
significant difference was determined between the groups in terms of pain,
vitality, social function, physical function or general health scores in the
preoperative and postoperative periods.</p></sec><sec><title>Conclusion:</title><p>The positive increase in quality of life parameters in the transcatheter
aortic valve implantation group at the 3<sup>rd</sup> month postoperatively
was significantly higher compared to the surgical aortic valve replacement
group.</p></sec></abstract><kwd-group><kwd>Aortic Valve, Surgery</kwd><kwd>Aortic Valve Stenosis</kwd><kwd>Quality of Life</kwd><kwd>Heart Valve Prosthesis Implantation</kwd></kwd-group></article-meta></front><body><table-wrap id="t3" orientation="portrait" position="anchor"><table frame="hsides" rules="groups" style="background-color:#e6e7e8"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr style="border-bottom-style:solid;border-top:solid; border-bottom-width:medium"><th colspan="2" align="left" rowspan="1">
<bold>Abbreviations, acronyms &#x00026; symbols</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">AS</td><td rowspan="1" colspan="1">= Aortic stenosis</td></tr><tr><td rowspan="1" colspan="1">AVR</td><td rowspan="1" colspan="1">= Aortic valve replacement</td></tr><tr><td rowspan="1" colspan="1">DM</td><td rowspan="1" colspan="1">= Diabetes mellitus</td></tr><tr><td rowspan="1" colspan="1">EuroSCORE</td><td rowspan="1" colspan="1">= European System for Cardiac Operative Risk Evaluation</td></tr><tr><td rowspan="1" colspan="1">NYHA</td><td rowspan="1" colspan="1">= New York Heart Association</td></tr><tr><td rowspan="1" colspan="1">PARTNER</td><td rowspan="1" colspan="1">= Placement of Aortic Transcatheter Valve</td></tr><tr><td rowspan="1" colspan="1">SF-36</td><td rowspan="1" colspan="1">= Short Form 36</td></tr><tr><td rowspan="1" colspan="1">TA</td><td rowspan="1" colspan="1">= Transapical</td></tr><tr><td rowspan="1" colspan="1">TAVI</td><td rowspan="1" colspan="1">= Transcatheter aortic valve implantation</td></tr><tr style="border-bottom-style:solid; border-bottom-width:medium"><td rowspan="1" colspan="1">TF</td><td rowspan="1" colspan="1">= Transfemoral</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Aortic stenosis (AS) is a common valve disease and if left untreated, the prognosis
of severe AS is poor. A surgical approach involving open heart surgery with low
levels of mortality and acceptable long-term morbidity levels has been successfully
applied in severe AS. Nonetheless, the risk of perioperative morbidity and mortality
increases in elderly patients or those with accompanying diseases and they may be
regarded as inoperable.</p><p>Transcatheter aortic valve implantation (TAVI) was initially introduced by Cribier
and colleagues and, currently, TAVI represents a valid therapeutic option for
patients with severe aortic stenosis who are inoperable or are at very high risk for
conventional surgery<sup>[<xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r2" ref-type="bibr">2</xref>]</sup>. TAVI is performed using one
of two different approaches: the retrograde transfemoral (TF) approach via the
femoral artery or the antegrade transapical (TA)<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>.</p><p>Quality of life is a subjective perception regarding an individual's state of
well-being, depending on sociocultural structures<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. Multidimensional evaluation of quality of
life in terms of physical, psychological and social functioning is reported to be a
good marker of an individual's health status<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>.</p><p>Various scales can be employed in the evaluation of patients' quality of life and
health outcomes. One of the most widely used is the Medical Outcome Study Short
Form-36 (SF-36). This is an easily applied test that provides important information
about quality of life assessment in patients undergoing open heart surgery and
percutaneous cardiac procedures<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>. SF-36 consists of 36 items, including 8 separate
health-related dimensions. The form is divided into the following domains: physical
function (10 items), social function (2 items), task restrictions due to physical
problems (4 items), task restrictions due to emotional problems (3 items), mental
health (5 items), vitality (4 items), pain (2 items), and general health (5 items).
The items in SF-36 inquire into positive or negative status concerning health and
are assessed based on the preceding 4 weeks. Item scores are coded for each
dimension and converted into a scale from 0 (worst health status) to 100 (best
health status). There have been limited data concerning the contribution to
patients' quality of life of TAVI.</p><p>The purpose of this prospective study was to use the SF-36 test to assess quality of
life in patients over 70 years of age undergoing aortic valve replacement (AVR) or
TAVI due to AS in our hospital, before the procedure and at the 3<sup>rd</sup>
postoperative month.</p></sec><sec sec-type="methods"><title>METHODS</title><p>AVR was planned on 79 patients aged over 70 diagnosed with advanced aortic stenosis
between January and June 2014. Approval for the study was granted by the hospital's
research ethics committee. Participants were informed about the study and signed an
informed consent form.</p><p>All patients were assessed in terms of aortic structure, porcelain aorta, penetrating
ulcer, and suitability of iliac arteries for catheter using computed tomography
angiography. Patients were investigated in terms of age, sex, hypertension, diabetes
mellitus (DM) and history of cigarette use, and parameters obtained from tests,
analyses and examinations were scored using the European System for Cardiac
Operative Risk Evaluation (EuroSCORE) risk scoring system. A hospital council,
comprised of specialist cardiologists, anesthesiologists and radiologists, discussed
every patient's case and decided on the type of procedure to be performed.</p><p>Only patients with advanced AS aged 70 or over were enrolled in the study. Patients
with other cardiac procedures in the same session besides AVR were excluded.</p><p>Severe AS was defined by the criteria used in the Placement of Aortic Transcatheter
Valve (PARTNER) Trial<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>: an aortic valve area of &#x0003c;0.8 cm2 (or aortic valve
area index &#x0003c;0.5 cm<sup>2</sup>/m<sup>2)</sup>, a mean aortic gradient of &#x0003e;40
mmHg, or a peak aortic jet velocity of &#x0003e;4 m/s. All patients had a New York Heart
Association (NYHA) functional class &#x02265;2. The exclusion criteria included
recent acute myocardial infarction (&#x02264;1 month), recent stroke or transient
ischemic attack (within 6 months), congenital bicuspid aortic valves, preexisting
prosthetic heart valve, severe ventricular dysfunction (left ventricular ejection
fraction &#x0003c;20%), renal insufficiency (creatinine &#x0003e;3 mg/dL), and life expectancy
of &#x0003c;12 months.</p><sec><title>Procedure</title><p>Prior to both procedures, patients were informed about how the procedure would be
performed and its possible risks. AVR using St. Jude Medical&#x000ae; Mechanical
heart valve (St. Jude Medical Inc.; Minneapolis, MN, USA) and TAVI using the
Edwards Sapien valve (Edwards Lifesciences, Irvine, CA, USA) were performed
under general anesthesia and using standard procedures. Patients were taken to
the intensive care unit after both procedures and remained there for at least
one night. Patients with no complications and who improved on the first day were
discharged.</p></sec><sec><title>Quality of life assessment</title><p>The SF-36 was used in the measurement and evaluation of quality of life. The
SF-36 was administered to 51 patients scheduled for AVR and 28 patients
scheduled for TAVI one day before and 3 months after the procedure, and quality
of life status was recorded. Patients completed the form either alone or with
the help of relatives.</p></sec><sec><title>Statistical analysis</title><p>Statistical analysis was performed on IBM SPSS Statistics 22 (IBM SPSS, Turkey)
software. The Shapiro Wilks test was used to determine normal distribution of
data. Descriptive statistical techniques were used to analyze the study data
(mean plus standard deviation). In addition, the Mann Whitney U test was used to
compare parameters between the two groups and the Wilcoxon signed test for
intragroup was used for pre- and postoperative comparisons. Chi square test,
Fisher's exact chi square test and Yates continuity correction were used in the
comparison of qualitative data. A value of <italic>P</italic>&#x0003c;0.05 was
considered statistically significant.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Seventy-nine patients were enrolled in the study, 38 (48.1%) of them were male and 41
(51.9%) were female. Mean age of patients was 74.3&#x000b1;5.2 years (70-91). The AVR
group consisted of 51 (64.6%) patients and the TAVI group of 28 (35.4%). In-hospital
mortality occurred in four patients in the AVR group and in one in the TAVI group. A
further one patient in the AVR group and 3 in the TAVI group died in the second
month after discharge. One patient in the AVR group was still being monitored in the
chronic intensive care unit after 3 months.</p><p>Mean ages were 79.6&#x000b1;5.7 years in the TAVI group and 71.4&#x000b1;1.2 in the AVR
group (<italic>P</italic>=0.001). Mean EuroSCORE values were 9.75&#x000b1;1.2 in the
TAVI group and 5.65&#x000b1;0.8 in the AVR group (<italic>P</italic>=0.001). No
significant differences were determined between the two groups in terms of
demographic findings other than age and EuroSCORE (<italic>P</italic>&#x0003e;0.05).
(<xref ref-type="table" rid="t1">Table 1</xref>)</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Patients&#x02019; demographic and clinical data according to groups.</p></caption><table frame="hsides" rules="all"><colgroup width="20%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr style="border-bottom-style:solid;border-top-style:solid;border-bottom-width:medium"><th rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">AVR</th><th align="center" rowspan="1" colspan="1">TAVI</th><th align="center" rowspan="1" colspan="1">
<italic>P </italic>
</th></tr></thead><tbody><tr style="border-bottom-style:solid;border-bottom-width:medium"><td rowspan="1" colspan="1">Age <sub>(mean&#x000b1;SD)</sub></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">71.43&#x000b1;1.25 (71)</td><td align="center" rowspan="1" colspan="1">79.64&#x000b1;5.72 (81)</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN2">**</xref></td></tr><tr style="border-bottom-style:solid;border-bottom-width:medium"><td rowspan="1" colspan="1">EF <sub>(mean&#x000b1;SD)</sub></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">46.76&#x000b1;4.88 (45)</td><td align="center" rowspan="1" colspan="1">46.96&#x000b1;4.97 (45)</td><td align="center" rowspan="1" colspan="1">0.880</td></tr><tr style="border-bottom-style:solid;border-bottom-width:medium"><td rowspan="1" colspan="1">EuroSCORE <sub>(mean&#x000b1;SD)</sub></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">5.65&#x000b1;0.82 (5)</td><td align="center" rowspan="1" colspan="1">9.75&#x000b1;1.27 (9)</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN2">**</xref></td></tr><tr><td rowspan="2" style="border-bottom-style:solid;border-bottom-width:medium" colspan="1">Gender
<sub>n=<sub>number,%</sub></sub></td><td align="center" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">n=27 (52.9%)</td><td align="center" rowspan="1" colspan="1">n=11 (39.3%)</td><td rowspan="2" align="center" style="border-bottom-style:solid;border-bottom-width:medium" colspan="1">0.354</td></tr><tr><td align="center" style="border-bottom-style:solid;border-bottom-width:medium" rowspan="1" colspan="1">Female</td><td align="center" style="border-bottom-style:solid;border-bottom-width:medium" rowspan="1" colspan="1">n=24
(47.1%)</td><td align="center" style="border-bottom-style:solid;border-bottom-width:medium" rowspan="1" colspan="1">n=17
(60.7%)</td></tr><tr><td rowspan="2" style="border-bottom-style:solid;border-bottom-width:medium" colspan="1">DM
<sub>number,%</sub></td><td align="center" rowspan="1" colspan="1">(+)</td><td align="center" rowspan="1" colspan="1">n=36 (70.6%)</td><td align="center" rowspan="1" colspan="1">n=21 (75%)</td><td rowspan="2" align="center" style="border-bottom-style:solid;border-bottom-width:medium" colspan="1">0.876</td></tr><tr><td align="center" style="border-bottom-style:solid;border-bottom-width:medium" rowspan="1" colspan="1">(-)</td><td align="center" style="border-bottom-style:solid;border-bottom-width:medium" rowspan="1" colspan="1">n=15
(29.4%)</td><td align="center" style="border-bottom-style:solid;border-bottom-width:medium" rowspan="1" colspan="1">n=7
(25%)</td></tr><tr><td rowspan="2" colspan="1">HT <sub>number,%</sub></td><td align="center" rowspan="1" colspan="1">(+)</td><td align="center" rowspan="1" colspan="1">n=45 (88.2%)</td><td align="center" rowspan="1" colspan="1">n=25 (89.3%)</td><td rowspan="2" align="center" colspan="1">1,000</td></tr><tr style="border-bottom-style:solid;border-bottom-width:medium"><td align="center" rowspan="1" colspan="1">(-)</td><td align="center" rowspan="1" colspan="1">n=6 (11.8%)</td><td align="center" rowspan="1" colspan="1">n=3 (10.7%)</td></tr><tr><td rowspan="2" colspan="1">Smoking <sub>number,%</sub></td><td align="center" rowspan="1" colspan="1">(+)</td><td align="center" rowspan="1" colspan="1">n=30 (58.8%)</td><td align="center" rowspan="1" colspan="1">n=14 (50%)</td><td rowspan="2" align="center" colspan="1">0.604</td></tr><tr style="border-bottom-style:solid;border-bottom-width:medium"><td align="center" rowspan="1" colspan="1">(-)</td><td align="center" rowspan="1" colspan="1">n=21 (41.2%)</td><td align="center" rowspan="1" colspan="1">n=14 (50%)</td></tr><tr><td rowspan="3" colspan="1">NYHA <sub>number,%</sub></td><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">n=7 (13.7%)</td><td align="center" rowspan="1" colspan="1">n=5 (17.9%)</td><td rowspan="3" align="center" colspan="1">0.703</td></tr><tr><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">n=39 (76.5%)</td><td align="center" rowspan="1" colspan="1">n=19 (67.9%)</td></tr><tr style="border-bottom-style:solid;border-bottom-width:medium"><td align="center" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">n=5 (9.8%)</td><td align="center" rowspan="1" colspan="1">n=4 (14.3%)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>AVR=aortic valve replacement; TAVI=transcatheter aortic valve
implantation; EF=ejection fraction; HT=hypertension; DM=Diabetes
Mellitus; NYHA=New York Heart Association;</p></fn><fn id="TFN2"><p>SD=standard deviation **P&#x0003c;0.01</p></fn></table-wrap-foot></table-wrap><p>Although preoperative physical task difficulty scores in the AVR group were
significantly higher than those in the TAVI group (35.3&#x000b1;6.1
<italic>vs.</italic> 30.7&#x000b1;3.4; <italic>P</italic>=0.001), no
statistically significant difference was observed between postoperative physical
task difficulty scores. The level of positive change in physical task difficulty
scores in the TAVI group was significantly higher than that in the AVR group
(13.2&#x000b1;9.8 <italic>vs.</italic> 5.1&#x000b1;7.3; <italic>P</italic>=0.001)
(<xref ref-type="table" rid="t2">Table 2</xref>, <xref ref-type="fig" rid="f1">Figure 1</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Evaluation of the SF-36 scores according to groups.</p></caption><table frame="hsides" rules="all"><colgroup width="20%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr style="border-top-style:solid;border-bottom-width:medium"><th style="border-bottom-style:hidden;border-right-style:hidden" rowspan="1" colspan="1">&#x000a0;</th><th align="center" style="border-bottom-style:hidden" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">AVR</th><th align="center" rowspan="1" colspan="1">TAVI</th><th align="center" rowspan="1" colspan="1">
<italic>P </italic>
</th></tr></thead><tbody><tr style="border-top-style:solid;border-bottom-width:medium"><td style="border-right-style:hidden" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">Mean&#x000b1;SD (Median)</td><td align="center" rowspan="1" colspan="1">Mean&#x000b1;SD (Median)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top-style:solid;border-bottom-width:medium"><td rowspan="4" colspan="1">Physical Function</td><td align="center" rowspan="1" colspan="1">Preop</td><td align="center" rowspan="1" colspan="1">28.29&#x000b1;5.77 (27.8)</td><td align="center" rowspan="1" colspan="1">26.53&#x000b1;5.87 (25.7)</td><td align="center" rowspan="1" colspan="1">0.126</td></tr><tr><td align="center" rowspan="1" colspan="1">Postop</td><td align="center" rowspan="1" colspan="1">42.3&#x000b1;7.07 (38.3)</td><td align="center" rowspan="1" colspan="1">40.3&#x000b1;11.34 (42.5)</td><td align="center" rowspan="1" colspan="1">0.783</td></tr><tr><td align="center" rowspan="1" colspan="1">Dif</td><td align="center" rowspan="1" colspan="1">13.55&#x000b1;7.74 (12.6)</td><td align="center" rowspan="1" colspan="1">13.64&#x000b1;10.91 (14.7)</td><td align="center" rowspan="1" colspan="1">0.933</td></tr><tr><td align="center" rowspan="1" colspan="1">
<sup>2</sup>
<italic>P</italic>
</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN5">*</xref></td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN6">**</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top-style:solid;border-bottom-width:medium"><td rowspan="4" colspan="1">Role Disabilities (Physical)</td><td align="center" rowspan="1" colspan="1">Preop</td><td align="center" rowspan="1" colspan="1">35.31&#x000b1;6.14 (35)</td><td align="center" rowspan="1" colspan="1">30.75&#x000b1;3.48 (28)</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN6">**</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">Postop</td><td align="center" rowspan="1" colspan="1">40.59&#x000b1;5.91 (42,1)</td><td align="center" rowspan="1" colspan="1">44.16&#x000b1;9.18 (42,1)</td><td align="center" rowspan="1" colspan="1">0.060</td></tr><tr><td align="center" rowspan="1" colspan="1">Dif</td><td align="center" rowspan="1" colspan="1">5.1&#x000b1;7.34 (7)</td><td align="center" rowspan="1" colspan="1">13.24&#x000b1;9.82 (14.1)</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN6">**</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">
<sup>2</sup>
<italic>P</italic>
</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN6">**</xref></td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN6">**</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top-style:solid;border-bottom-width:medium"><td rowspan="4" colspan="1">Pain</td><td align="center" rowspan="1" colspan="1">Preop</td><td align="center" rowspan="1" colspan="1">44.11&#x000b1;5.59 (46.5)</td><td align="center" rowspan="1" colspan="1">42.12&#x000b1;4.96 (42.2)</td><td align="center" rowspan="1" colspan="1">0.156</td></tr><tr><td align="center" rowspan="1" colspan="1">Postop</td><td align="center" rowspan="1" colspan="1">44.27&#x000b1;9.54 (46.5)</td><td align="center" rowspan="1" colspan="1">45.28&#x000b1;8.87 (46,05)</td><td align="center" rowspan="1" colspan="1">0.728</td></tr><tr><td align="center" rowspan="1" colspan="1">Dif</td><td align="center" rowspan="1" colspan="1">0.28&#x000b1;10.94 (0)</td><td align="center" rowspan="1" colspan="1">2.82&#x000b1;10.87 (4.3)</td><td align="center" rowspan="1" colspan="1">0.312</td></tr><tr><td align="center" rowspan="1" colspan="1">
<sup>2</sup>
<italic>P</italic>
</td><td align="center" rowspan="1" colspan="1">0.957</td><td align="center" rowspan="1" colspan="1">0.213</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top-style:solid;border-bottom-width:medium"><td rowspan="4" colspan="1">General Health</td><td align="center" rowspan="1" colspan="1">Preop</td><td align="center" rowspan="1" colspan="1">29.59&#x000b1;2.07 (31.2)</td><td align="center" rowspan="1" colspan="1">29.74&#x000b1;3.09 (28.9)</td><td align="center" rowspan="1" colspan="1">0.852</td></tr><tr><td align="center" rowspan="1" colspan="1">Postop</td><td align="center" rowspan="1" colspan="1">45.27&#x000b1;6.83 (43.9)</td><td align="center" rowspan="1" colspan="1">48.62&#x000b1;13.8 (48.55)</td><td align="center" rowspan="1" colspan="1">0.217</td></tr><tr><td align="center" rowspan="1" colspan="1">Dif</td><td align="center" rowspan="1" colspan="1">15.61&#x000b1;7.21 (15)</td><td align="center" rowspan="1" colspan="1">19.17&#x000b1;14.16 (18.05)</td><td align="center" rowspan="1" colspan="1">0.176</td></tr><tr><td align="center" rowspan="1" colspan="1">
<sup>2</sup>
<italic>P</italic>
</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN6">**</xref></td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN6">**</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top-style:solid;border-bottom-width:medium"><td rowspan="4" colspan="1">Vitality</td><td align="center" rowspan="1" colspan="1">Preop</td><td align="center" rowspan="1" colspan="1">42.04&#x000b1;3.38 (44.3)</td><td align="center" rowspan="1" colspan="1">43.29&#x000b1;3.38 (44.3)</td><td align="center" rowspan="1" colspan="1">0.134</td></tr><tr><td align="center" rowspan="1" colspan="1">Postop</td><td align="center" rowspan="1" colspan="1">48.35&#x000b1;5.28 (49.1)</td><td align="center" rowspan="1" colspan="1">49.27&#x000b1;7.19 (49.1)</td><td align="center" rowspan="1" colspan="1">0.450</td></tr><tr><td align="center" rowspan="1" colspan="1">Dif</td><td align="center" rowspan="1" colspan="1">6.4&#x000b1;5.61 (7.1)</td><td align="center" rowspan="1" colspan="1">5.65&#x000b1;7.42 (4.8)</td><td align="center" rowspan="1" colspan="1">0.562</td></tr><tr><td align="center" rowspan="1" colspan="1">
<sup>2</sup>
<italic>P</italic>
</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN6">**</xref></td><td align="center" rowspan="1" colspan="1">0.002<xref ref-type="table-fn" rid="TFN6">**</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top-style:solid;border-bottom-width:medium"><td rowspan="4" colspan="1">Social Function</td><td align="center" rowspan="1" colspan="1">Preop</td><td align="center" rowspan="1" colspan="1">27.78&#x000b1;2.68 (30)</td><td align="center" rowspan="1" colspan="1">29.04&#x000b1;4.17 (30)</td><td align="center" rowspan="1" colspan="1">0.234</td></tr><tr><td align="center" rowspan="1" colspan="1">Postop</td><td align="center" rowspan="1" colspan="1">37.51&#x000b1;5.85 (35.4)</td><td align="center" rowspan="1" colspan="1">38.14&#x000b1;12.07 (35.4)</td><td align="center" rowspan="1" colspan="1">0.955</td></tr><tr><td align="center" rowspan="1" colspan="1">Dif</td><td align="center" rowspan="1" colspan="1">9.58&#x000b1;6.63 (10.8)</td><td align="center" rowspan="1" colspan="1">9.26&#x000b1;12.12 (5.4)</td><td align="center" rowspan="1" colspan="1">0.578</td></tr><tr><td align="center" rowspan="1" colspan="1">
<sup>2</sup>
<italic>P</italic>
</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN6">**</xref></td><td align="center" rowspan="1" colspan="1">0.002<xref ref-type="table-fn" rid="TFN6">**</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top-style:solid;border-bottom-width:medium"><td rowspan="4" colspan="1">Role Difficulties (Emotional)</td><td align="center" rowspan="1" colspan="1">Preop</td><td align="center" rowspan="1" colspan="1">32.01&#x000b1;4.4 (34.3)</td><td align="center" rowspan="1" colspan="1">30.14&#x000b1;5.27 (34.3)</td><td align="center" rowspan="1" colspan="1">0.095</td></tr><tr><td align="center" rowspan="1" colspan="1">Postop</td><td align="center" rowspan="1" colspan="1">40.33&#x000b1;5.25 (44.8)</td><td align="center" rowspan="1" colspan="1">44.79&#x000b1;10.29 (44.8)</td><td align="center" rowspan="1" colspan="1">0.019*</td></tr><tr><td align="center" rowspan="1" colspan="1">Dif</td><td align="center" rowspan="1" colspan="1">8.51&#x000b1;6.46 (10.5)</td><td align="center" rowspan="1" colspan="1">14.47&#x000b1;11.96 (15.8)</td><td align="center" rowspan="1" colspan="1">0.035*</td></tr><tr><td align="center" rowspan="1" colspan="1">
<sup>2</sup>
<italic>P</italic>
</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN6">**</xref></td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN6">**</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-top-style:solid;border-bottom-width:medium"><td rowspan="4" colspan="1">Mental Health</td><td align="center" rowspan="1" colspan="1">Preop</td><td align="center" rowspan="1" colspan="1">38.27&#x000b1;5.85 (39.1)</td><td align="center" rowspan="1" colspan="1">34.77&#x000b1;4.03 (36.8)</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN6">**</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">Postop</td><td align="center" rowspan="1" colspan="1">37.78&#x000b1;9.15 (34.5)</td><td align="center" rowspan="1" colspan="1">44.96&#x000b1;14.77 (48.15)</td><td align="center" rowspan="1" colspan="1">0.005<xref ref-type="table-fn" rid="TFN6">**</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">Dif</td><td align="center" rowspan="1" colspan="1">0.42&#x000b1;10.41 (2.3)</td><td align="center" rowspan="1" colspan="1">9.68&#x000b1;15.1 (10.2)</td><td align="center" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="TFN6">**</xref></td></tr><tr><td align="center" rowspan="1" colspan="1">
<sup>2</sup>
<italic>P</italic>
</td><td align="center" rowspan="1" colspan="1">0.983</td><td align="center" rowspan="1" colspan="1">0.008<xref ref-type="table-fn" rid="TFN6">**</xref></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>AVR=aortic valve replacement; TAVI=transcatheter aortic valve
implantation; Dif=difference; Preop=preoperative;</p></fn><fn id="TFN4"><p>Postop=postoperative; SD=standard deviation</p></fn><fn id="TFN5"><label>*</label><p>P&#x0003c;0.05</p></fn><fn id="TFN6"><label>**</label><p>P&#x0003c;0.01</p></fn></table-wrap-foot></table-wrap><p><fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Short Form (36) Health Survey (SF-36) Test values in patients with aortic
valve replacement (AVR) and TAVI (transcatheter aortic valve
implantation); blue column represents AVR, red column represents
TAVI.</p></caption><graphic xlink:href="rbccv-31-01-0001-g01"/></fig></p><p>There was no difference between AVR and TAVI in terms of emotional task restriction
in the preoperative period, but the level of positive change in the TAVI group was
significantly higher than that in the AVR group (14.4&#x000b1;11.9
<italic>vs.</italic> 8.5&#x000b1;6.4; <italic>P</italic>=0.035) (<xref ref-type="table" rid="t2">Table 2</xref>, <xref ref-type="fig" rid="f1">Figure
1</xref>).</p><p>Preoperative mental health in the AVR group was significantly higher compared to the
TAVI group (38.2&#x000b1;5.8 <italic>vs.</italic> 34.7&#x000b1;4;
<italic>P</italic>=0.001). However, the level of positive change in mental health
scores in the postoperative period in the TAVI group was significantly higher
compared to the AVR group (0.4&#x000b1;10.4 <italic>vs.</italic> 9.6&#x000b1;15.1;
<italic>P</italic>=0.001; <italic>P</italic>&#x0003c;0.01) (<xref ref-type="table" rid="t2">Table 2</xref>, <xref ref-type="fig" rid="f1">Figure 1</xref>).</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The positive improvement in this study of patients with advanced AS aged over 70 in
post-procedural physical and emotional task restriction scores in the TAVI group was
higher than that in the AVR group. Although preoperative mental health scores in the
AVR group were higher than those of the TAVI group, there was a very high increase
in post-procedural mental health scores in the TAVI group. No significant
differences in quality of life improvements were determined between the two groups
in the other parameters, including pre- and postoperative pain, vitality, social
functioning, physical functioning, and general health scores. Improvement in both
disease-specific symptoms and general health has been observed following TAVI and
AVR in patients with advanced AS. The effect on quality of life of procedural
techniques has also been investigated in patients undergoing TAVI. Shorter recovery
and higher levels of improvement in quality of life have been reported in patients
undergoing transfemoral TAVI compared to those undergoing transapical TAVI requiring
thoracotomy<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>.</p><p>Levels of improvement in quality of life in the postoperative period in patients
unsuitable for transfemoral procedures and undergoing transapical were not higher
than those in patients undergoing AVR. While a small thoracotomy incision is
performed in the transapical approach, the absence of a positive change in quality
of life that might be expected in transapical TAVI compared to classic AVR, which
involves median sternotomy and cardiopulmonary bypass, may be attributed to greater
length and severity of thoracotomy-related postoperative pain compared to those in
sternotomy, resulting in greater restriction of the patient<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>.</p><p>The greatest benefit in quality of life following TAVI was observed in patients'
physical functions, and the least in body pain. Bekeredjian et al.<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup> reported that TAVI had
positive effects on quality of life in mental terms in patients aged over 80.</p><p>In our study, the greatest benefit observed in the TAVI group was in general health
functions and the least was in body pain. TAVI was also observed to bestow
significant positive benefits in terms of mental health.</p><p>One prospective study determined that quality of life at the 3<sup>rd</sup> month
following TAVI increased significantly compared to the preoperative period; it also
showed an increase in patients' NYHA functional capacities<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>Age-related activity restrictions occur in patients aged 70 years and over. One study
comparing preoperative and 6<sup>th</sup> month postoperative quality of life using
SF-36 in patients with a mean age of over 70 undergoing AVR reported positive
changes at the 6<sup>th</sup> month in physical functioning, social functioning,
physical health-related task restriction, vitality, and health status. That same
study also stated that functional capacity decreased from NYHA class 3 to class 1 in
82% of patients<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p><p>Another study of patients at more advanced ages (80 years old or more) undergoing AVR
reported a particular increase in functional capacities independently of age in the
postoperative period in the great majority of patients. Significant improvements
were also observed in general and mental health, social functioning, emotional task,
and pain<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>.</p><p>In our study, significant, positive changes were determined in all parameters, apart
from pain and mental health, in all the patients in the AVR group following the
procedure.</p><p>No significant difference has been reported between mortality levels in the
1<sup>st</sup> month and in the 1<sup>st</sup> year due to cardiac or any other
causes following TAVI or AVR in patients with advanced aortic stenosis and high
comorbidity<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>.</p><p>One study comparing quality of life values following TAVI and AVR reported that
although the TAVI group was generally ahead in the 1<sup>st</sup> month, quality of
life was generally similar between the two groups at the 6<sup>th</sup> and
12<sup>th</sup> months, and that the AVR group caught up with the TAVI over
time<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>.</p><p>We think that studies performed at the 1<sup>st</sup> month may not produce sound
findings since this includes the time when patients undergoing AVR are still in
recovery. Quality of life values have been shown to increase rapidly in patients
undergoing AVR after a 2-month recovery period and with sternum stabilization. This
was also confirmed in our study.</p><p>In terms of limitations, our findings are limited to the early period in patients
undergoing TAVI and AVR. Additionally, SF-36 was used in the measurement and
evaluation of patients' quality of life. We used this form because it is easy to
apply, contains easily understood questions and, in particular, determines the
degree of dependence on another person in patients' daily lives. The fact that,
apart from assessment of quality of life, other tests such as hospital anxiety and
depression scales were not administered represents another limitation.</p><p>Advanced AS is a mechanical problem that can severely affect the individual, both
mentally and physically. Whether this mechanical problem is overcome with AVR or
TAVI, the procedures in both groups allow patients' symptoms to be resolved, life
expectancy to be extended and quality of life to be improved.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>The increase in quality of life parameters in the TAVI group at the end of the
3<sup>rd</sup> month was greater than that in the AVR group. This may best be
attributed to TAVI being a non-invasive method and there being no need for
cardiopulmonary bypass during the procedure.</p><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th colspan="2" align="left" rowspan="1">
<bold>Authors&#x02019; roles &#x00026; responsibilities</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">CK</td><td rowspan="1" colspan="1">Conception and study design; execution of operations and/or trials;
analysis and/or data interpretation; writing of the manuscript or
critical review of its content; final manuscript approval</td></tr><tr><td rowspan="1" colspan="1">BK</td><td rowspan="1" colspan="1">Writing of the manuscript or critical review of its content; final
approval of the manuscript</td></tr><tr><td rowspan="1" colspan="1">MY</td><td rowspan="1" colspan="1">Writing of the manuscript or critical review of its content; final
approval of the manuscript</td></tr><tr><td rowspan="1" colspan="1">TK</td><td rowspan="1" colspan="1">Final approval of the manuscript</td></tr><tr><td rowspan="1" colspan="1">MEM</td><td rowspan="1" colspan="1">Analysis and/or data interpretation; writing of the manuscript or
critical review of its content; final approval of the
manuscript</td></tr><tr><td rowspan="1" colspan="1">GE</td><td rowspan="1" colspan="1">Writing of the manuscript or critical review of its content; final
approval of the manuscript</td></tr><tr><td rowspan="1" colspan="1">ME</td><td rowspan="1" colspan="1">Writing of the manuscript or critical review of its content; final
approval of the manuscript</td></tr><tr><td rowspan="1" colspan="1">MMD</td><td rowspan="1" colspan="1">Execution of operations and/or trials; writing of the manuscript or
critical review of its content; final approval of the
manuscript</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn><fn fn-type="supported-by"><p>No financial support.</p></fn><fn fn-type="other"><p>Our research was carried out at Dr.Siyami Ersek Cardiovascular and Thoracic
Surgery Hospital, Department of Cardiovascular Surgery, &#x00130;stanbul, Turkey.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pontes</surname><given-names>JC</given-names></name><name><surname>Duarte</surname><given-names>JJ</given-names></name><name><surname>Silva</surname><given-names>AD</given-names></name><name><surname>Gardenal</surname><given-names>N</given-names></name><name><surname>Dias</surname><given-names>AM</given-names></name><name><surname>Benfatti</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Initial and pioneer experience of transcatheter aortic valve
implantation (Inovare) through femoral or iliac artery</article-title><source>Rev Bras Cir Cardiovasc</source><year>2013</year><volume>28</volume><issue>2</issue><fpage>208</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">23939317</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Pei</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zaiping</surname><given-names>J</given-names></name></person-group><article-title>Transcatheter aortic valve implantation with balloon-expandable
valve: early experience from China</article-title><source>Rev Bras Cir Cardiovasc</source><year>2015</year><volume>30</volume><issue>4</issue><fpage>425</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">27163416</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sambu</surname><given-names>N</given-names></name><name><surname>Curzen</surname><given-names>N</given-names></name></person-group><article-title>Transcatheter aortic valve implantation: the state of
play</article-title><source>Future Cardiol</source><year>2010</year><volume>6</volume><issue>2</issue><fpage>243</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">20230265</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The World Health Organization</collab></person-group><article-title>Quality of Life assessment (WHOQOL): position paper from the
World Health Organization</article-title><source>Soc Sci Med</source><year>1995</year><volume>41</volume><issue>10</issue><fpage>1403</fpage><lpage>1409</lpage><pub-id pub-id-type="pmid">8560308</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valenti</surname><given-names>M</given-names></name><name><surname>Porzio</surname><given-names>G</given-names></name><name><surname>Aielli</surname><given-names>F</given-names></name><name><surname>Verna</surname><given-names>L</given-names></name><name><surname>Cannita</surname><given-names>K</given-names></name><name><surname>Manno</surname><given-names>R</given-names></name><etal/></person-group><article-title>Physical exercise and quality of life in breast cancer
survivors</article-title><source>Int J Med Sci</source><year>2008</year><volume>5</volume><issue>1</issue><fpage>24</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">18219372</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>JE Jr</given-names></name><name><surname>Sherbourne</surname><given-names>CD</given-names></name></person-group><article-title>The MOS 36-item short-form health survey (SF-36). I. Conceptual
framework and item selection</article-title><source>Med Care</source><year>1992</year><volume>30</volume><issue>6</issue><fpage>473</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">1593914</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leon</surname><given-names>MB</given-names></name><name><surname>Smith</surname><given-names>CR</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>DC</given-names></name><name><surname>Moses</surname><given-names>JW</given-names></name><name><surname>Svensson</surname><given-names>LG</given-names></name><etal/><collab>PARTNER Trial Investigators</collab></person-group><article-title>Transcatheter aortic-valve implantation for aortic stenosis in
patients who cannot undergo surgery</article-title><source>N Engl J Med</source><year>2010</year><volume>363</volume><issue>17</issue><fpage>1597</fpage><lpage>1607</lpage><pub-id pub-id-type="pmid">20961243</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taramasso</surname><given-names>M</given-names></name><name><surname>Latib</surname><given-names>A</given-names></name><name><surname>Cioni</surname><given-names>M</given-names></name><name><surname>Denti</surname><given-names>P</given-names></name><name><surname>Buzzatti</surname><given-names>N</given-names></name><name><surname>Godino</surname><given-names>C</given-names></name><etal/></person-group><article-title>Quality of life improvement is maintained up to two years after
transcatheter aortic valve implantation in high-risk surgical
candidates</article-title><source>EuroIntervention</source><year>2012</year><volume>8</volume><issue>4</issue><fpage>429</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">22917725</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bekeredjian</surname><given-names>R</given-names></name><name><surname>Krumsdorf</surname><given-names>U</given-names></name><name><surname>Chorianopoulos</surname><given-names>E</given-names></name><name><surname>Kallenbach</surname><given-names>K</given-names></name><name><surname>Karck</surname><given-names>M</given-names></name><name><surname>Katus</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Usefulness of percutaneous aortic valve implantation to improve
quality of life in patients &#x0003e;80 years of age</article-title><source>Am J Cardiol</source><year>2010</year><volume>106</volume><issue>12</issue><fpage>1777</fpage><lpage>1781</lpage><pub-id pub-id-type="pmid">21055715</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krane</surname><given-names>M</given-names></name><name><surname>Deutsch</surname><given-names>MA</given-names></name><name><surname>Bleiziffer</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>L</given-names></name><name><surname>Ruge</surname><given-names>H</given-names></name><name><surname>Mazzitelli</surname><given-names>D</given-names></name><etal/></person-group><article-title>Quality of life among patients undergoing transcatheter aortic
valve implantation</article-title><source>Am Heart J</source><year>2010</year><volume>160</volume><issue>3</issue><fpage>451</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">20826252</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>T</given-names></name><name><surname>Lopez</surname><given-names>BM</given-names></name><name><surname>Berberian</surname><given-names>C</given-names></name><name><surname>Cunningham</surname><given-names>MJ</given-names></name><name><surname>Starnes</surname><given-names>VA</given-names></name><name><surname>Cohen</surname><given-names>RG</given-names></name></person-group><article-title>Exercise hemodynamics and quality of life after aortic valve
replacement for aortic stenosis in the elderly using the Hancock II
bioprosthesis</article-title><source>Cardiol Res Pract</source><year>2014</year><volume>2014</volume><fpage>151282</fpage><lpage>151282</lpage><pub-id pub-id-type="pmid">25544931</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sundt</surname><given-names>TM</given-names></name><name><surname>Bailey</surname><given-names>MS</given-names></name><name><surname>Moon</surname><given-names>MR</given-names></name><name><surname>Mendeloff</surname><given-names>EN</given-names></name><name><surname>Huddleston</surname><given-names>CB</given-names></name><name><surname>Pasque</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Quality of life after aortic valve replacement at the age of
&#x0003e;80 years</article-title><source>Circulation</source><year>2000</year><volume>102</volume><issue>19</issue><supplement>Suppl 3</supplement><fpage>III70</fpage><lpage>III74</lpage><pub-id pub-id-type="pmid">11082365</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awad</surname><given-names>W</given-names></name><name><surname>Mathur</surname><given-names>A</given-names></name><name><surname>Baldock</surname><given-names>L</given-names></name><name><surname>Oliver</surname><given-names>S</given-names></name><name><surname>Kennon</surname><given-names>S</given-names></name></person-group><article-title>Comparing postoperative resource consumption following
transcatheter aortic valve implantation (TAVI) and conventional aortic valve
replacement in the UK</article-title><source>J Med Econ</source><year>2014</year><volume>17</volume><issue>5</issue><fpage>357</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">24621135</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gon&#x000e7;alves</surname><given-names>A</given-names></name><name><surname>Marcos-Alberca</surname><given-names>P</given-names></name><name><surname>Almeria</surname><given-names>C</given-names></name><name><surname>Feltes</surname><given-names>G</given-names></name><name><surname>Hern&#x000e1;ndez- Antol&#x000ed;n</surname><given-names>RA</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>E</given-names></name><etal/></person-group><article-title>Quality of life improvement at midterm follow-up after
transcatheter aortic valve implantation</article-title><source>Int J Cardiol</source><year>2013</year><volume>162</volume><issue>2</issue><fpage>117</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">21636149</pub-id></element-citation></ref></ref-list></back></article>